| Detected | Trial | Change |
|---|---|---|
| 2026-07-07 | NCT03331198 Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-07-07 | NCT06356129 Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus… |
date change Primary completion moved earlier: 2028-08-14 -> 2027-08-09 |
| 2026-07-07 | NCT06356129 Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus… |
date change Completion moved earlier: 2029-11-20 -> 2029-06-26 |
| 2026-07-07 | NCT06481306 A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell… |
Primary endpoint(s) modified |
| 2026-07-07 | NCT06481306 A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell… |
Enrollment increased: 184 -> 224 participants |
| 2026-07-07 | NCT06481306 A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell… |
date change Primary completion pushed: 2027-01-06 -> 2028-04-30 |
| 2026-07-07 | NCT06481306 A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell… |
date change Completion pushed: 2027-11-16 -> 2029-10-28 |
| 2026-07-03 | NCT05827016 A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-07-03 | NCT05827016 A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy… |
Trial sites reduced: 285 -> 271 locations |
| 2026-07-02 | NCT07226817 A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the… |
date change Primary completion pushed: 2026-07-01 -> 2026-12-17 |
| 2026-07-02 | NCT07226817 A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the… |
date change Completion pushed: 2026-07-01 -> 2026-12-17 |
| 2026-07-01 | NCT07011732 A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment… |
Enrollment increased: 352 -> 426 participants |
| 2026-07-01 | NCT05949684 ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants… |
Primary endpoint(s) modified |
| 2026-07-01 | NCT05949684 ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants… |
Enrollment increased: 360 -> 402 participants |
| 2026-07-01 | NCT05949684 ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants… |
date change Primary completion pushed: 2027-06-25 -> 2028-03-24 |
| 2026-07-01 | NCT05949684 ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants… |
date change Completion pushed: 2030-03-11 -> 2031-05-30 |
| 2026-07-01 | NCT07288567 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia… |
Trial sites expanded: 41 -> 44 locations |
| 2026-07-01 | NCT07284745 A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With… |
Trial sites reduced: 45 -> 40 locations |
| 2026-06-27 | NCT07291076 A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With… |
Trial sites expanded: 59 -> 64 locations |
| 2026-06-27 | NCT06976216 A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment… |
Trial sites expanded: 106 -> 116 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-07-02 | NCT07680764 A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With… | Phase 2 | Not Yet Recruiting |
| 2026-07-02 | NCT07680790 Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus… | Phase 3 | Not Yet Recruiting |
| 2026-07-02 | NCT07681440 A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic… | Terminated | |
| 2026-07-01 | NCT07679061 First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE) | Recruiting | |
| 2026-06-23 | NCT07663786 Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice | Active, Not Recruiting | |
| 2026-06-18 | NCT07655518 A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic… | Phase 1 | Not Yet Recruiting |
| 2026-06-09 | NCT07636863 Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig | Completed |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06875960 | A Study to Continue the Administration of Deucravacitinib in Participants With Systemic… | Systemic Lupus Erythematosus (SLE) | Recruiting |
| NCT07221877 | A Study to Evaluate the Effect of KarXT on Urological Safety | Schizophrenia | Recruiting |
| NCT07459543 | A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose… | Untreated Melanoma | Not Yet Recruiting |
| NCT07004972 | A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India… | Symptomatic Obstructive Hypertrophic Cardiomyopathy | Active, Not Recruiting |
| Phase 3 | |||
| NCT06408259 | Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in… | Multiple Sclerosis, Relapsing-Remitting | Recruiting |
| NCT06911502 | A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab… | Follicular Lymphoma | Recruiting |
| NCT06951711 | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes… | Bipolar Disorder Type I With Mania or Mania With Mixed Features | Recruiting |
| NCT04772079 | A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children… | Plaque Psoriasis | Recruiting |
| NCT07335562 | A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel /… | Systemic Sclerosis | Recruiting |
| NCT07116967 | Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With… | Plaque Psoriasis | Recruiting |
| NCT06979453 | A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165)… | Plaque Psoriasis | Recruiting |
| NCT06561386 | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs… | Non-small Cell Lung Cancer | Recruiting |
| NCT07140913 | A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of… | Mania | Recruiting |
| NCT06929273 | A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in… | Bipolar Disorder Type I With Mania | Recruiting |
| NCT04877288 | A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney… | Renal Allograft Recipients | Recruiting |
| NCT07011745 | A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment… | Alzheimer Disease | Recruiting |
| NCT06615479 | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in… | Relapsed or Refractory Multiple Myeloma (RRMM) | Recruiting |
| NCT06764485 | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice… | Metastatic Castration-resistant Prostate Cancer | Recruiting |
| NCT06869551 | A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165)… | Juvenile Psoriatic Arthritis | Recruiting |
| NCT06951698 | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes… | Bipolar-I Disorder With Mania or Mania With Mixed Features | Recruiting |
| NCT06976203 | A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment… | Alzheimer's Disease | Recruiting |
| NCT06976216 | A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment… | Alzheimer's Disease | Recruiting |
| NCT07361497 | A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation… | Non-small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT07361510 | A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With… | Non-Small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT06646276 | A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed… | Extensive-Stage Small Cell Lung Cancer | Recruiting |